We feel now is a pretty good time to analyse Biofrontera Inc.'s (NASDAQ:BFRI) business as it appears the company may be on the cusp of a considerable accomplishment. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The US$10m market-cap company posted a loss in its most recent financial year of US$18m and a latest trailing-twelve-month loss of US$17m shrinking the gap between loss and breakeven. The most pressing concern for investors is Biofrontera's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to the 2 industry analysts covering Biofrontera, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$666k in 2026. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 70% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Biofrontera given that this is a high-level summary, but, keep in mind that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for Biofrontera

Before we wrap up, there’s one issue worth mentioning. Biofrontera currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.

There are too many aspects of Biofrontera to cover in one brief article, but the key fundamentals for the company can all be found in one place – Biofrontera's company page on Simply Wall St. We've also compiled a list of relevant factors you should further examine:

Historical Track Record: What has Biofrontera's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Biofrontera's board and the CEO’s background.

Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.